 |
인쇄하기
취소
|
Sudo to sign joint A1 flu vaccine development with a US firm.
Sudo pharmaceutical company signed an agreement for the joint development of A1 flu vaccine at Seoul Press Center with MediVas Bio venture company of America.
The agreement describes that Sudo develops the A1 flu vaccine by the use of MediVas' biopolymer technology, taking exclusive distribution and production rights in Korea but fixing the same rights applicable to other territories in Asia...
The agreement describes that Sudo develops the A1 flu vaccine by the use of MediVas' biopolymer technology, taking exclusive distribution and production rights in Korea but fixing the same rights applicable to other territories in Asia...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.